GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » 10-Year RORE %

Vivos (RDGL) 10-Year RORE % : -96.78% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Vivos 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Vivos's 10-Year RORE % for the quarter that ended in Dec. 2023 was -96.78%.

The industry rank for Vivos's 10-Year RORE % or its related term are showing as below:

RDGL's 10-Year RORE % is ranked worse than
97.73% of 397 companies
in the Medical Devices & Instruments industry
Industry Median: 2.48 vs RDGL: -96.78

Vivos 10-Year RORE % Historical Data

The historical data trend for Vivos's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos 10-Year RORE % Chart

Vivos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.15 -19.02 -63.24 -47.43 -96.78

Vivos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.43 -56.22 -74.77 -77.64 -96.78

Competitive Comparison of Vivos's 10-Year RORE %

For the Medical Devices subindustry, Vivos's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos's 10-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Vivos's 10-Year RORE % falls into.



Vivos 10-Year RORE % Calculation

Vivos's 10-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.01--26.03 )/( -26.887-0 )
=26.02/-26.887
=-96.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 10-year before.


Vivos  (OTCPK:RDGL) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Vivos 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Vivos's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos (RDGL) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadwin Avenue, Richland, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336

Vivos (RDGL) Headlines

From GuruFocus

Vivos Inc. Provides Intellectual Property Protection Update

By PurpleRose PurpleRose 07-11-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-01-2022

Vivos Inc Initiates Isopet� Therapy in Horses

By Marketwired Marketwired 06-24-2021

Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives

By GuruFocusNews GuruFocusNews 01-24-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-11-2022

Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy

By Stock market mentor Stock market mentor 01-11-2023

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 07-01-2022

Vivos Inc Obtains Trademark Protection for IsoPet®

By Marketwired Marketwired 07-30-2018

Vivos Inc. Enhances its Intellectual Property Protection

By GuruFocusNews GuruFocusNews 02-24-2022